Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)

Phase Distribution

Ph phase_4
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (66.7%)
Phase 41 (33.3%)

Trials by Status

unknown133%
recruiting133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_2

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

NCT07033819
unknownphase_2

Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

NCT05842525
terminatedphase_4

Antipsychotic Induced Structural and Functional Brain Changes

NCT02435095

Clinical Trials (3)

Showing 3 of 3 trials
NCT07033819Phase 2

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Recruiting
NCT05842525Phase 2

Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Unknown
NCT02435095Phase 4

Antipsychotic Induced Structural and Functional Brain Changes

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3